MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
Initiation of registration study for ME-401 in patients with relapsed or refractory follicular lymphoma expected before year-end
SAN DIEGO, June 15, 2018 -- (Healthcare Sales & Marketing Network) -- MEI Pharma, Inc. (NASDAQ: MEIP) a pharmaceutical comp... Biopharmaceuticals, Oncology MEI Pharma, follicular lymphoma, chronic lymphocytic lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Hematology | Lymphoma | Marketing | Pharmaceuticals | Politics | Study